de Boer RA - Search Results

1

Seventy-five genetic loci influencing the human red blood cell.

van der Harst P, Zhang W, Mateo Leach I, Rendon A, Verweij N, Sehmi J, Paul DS, Elling U, Allayee H, Li X, Radhakrishnan A, Tan ST, Voss K, Weichenberger CX, Albers CA, Al-Hussani A, Asselbergs FW, Ciullo M, Danjou F, Dina C, Esko T, Evans DM, Franke L, Gögele M, Hartiala J, Hersch M, Holm H, Hottenga JJ, Kanoni S, Kleber ME, Lagou V, Langenberg C, Lopez LM, Lyytikäinen LP, Melander O, Murgia F, Nolte IM, O'Reilly PF, Padmanabhan S, Parsa A, Pirastu N, Porcu E, Portas L, Prokopenko I, Ried JS, Shin SY, Tang CS, Teumer A, Traglia M, Ulivi S, Westra HJ, Yang J, Zhao JH, Anni F, Abdellaoui A, Attwood A, Balkau B, Bandinelli S, Bastardot F, Benyamin B, Boehm BO, Cookson WO, Das D, de Bakker PI, de Boer RA, de Geus EJ, de Moor MH, Dimitriou M, Domingues FS, Döring A, Engström G, Eyjolfsson GI, Ferrucci L, Fischer K, Galanello R, Garner SF, Genser B, Gibson QD, Girotto G, Gudbjartsson DF, Harris SE, Hartikainen AL, Hastie CE, Hedblad B, Illig T, Jolley J, Kähönen M, Kema IP, Kemp JP, Liang L, Lloyd-Jones H, Loos RJ, Meacham S, Medland SE, Meisinger C, Memari Y, Mihailov E, Miller K, Moffatt MF, Nauck M, Novatchkova M, Nutile T, Olafsson I, Onundarson PT, Parr… See abstract for full author list ➔ van der Harst P, et al. Among authors: de moor mh, de boer ra, de bakker pi, de geus ej. Nature. 2012 Dec 20;492(7429):369-75. doi: 10.1038/nature11677. Epub 2012 Dec 5. Nature. 2012. PMID: 23222517 Free PMC article.

2

Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression.

de Boer RA, van Geel PP, Pinto YM, Suurmeijer AJ, Crijns HJ, van Gilst WH, van Veldhuisen DJ. de Boer RA, et al. J Cardiovasc Pharmacol. 2002 Apr;39(4):610-9. doi: 10.1097/00005344-200204000-00017. J Cardiovasc Pharmacol. 2002. PMID: 11904535

3

Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure.

Tjeerdsma G, de Boer RA, Boomsma F, van den Berg MP, Pinto YM, van Veldhuisen DJ. Tjeerdsma G, et al. Among authors: de boer ra. Int J Cardiol. 2002 Dec;86(2-3):143-9; discussion 149-52. doi: 10.1016/s0167-5273(02)00409-6. Int J Cardiol. 2002. PMID: 12419550

4

Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction.

de Boer RA, Pinto YM, Suurmeijer AJ, Pokharel S, Scholtens E, Humler M, Saavedra JM, Boomsma F, van Gilst WH, van Veldhuisen DJ. de Boer RA, et al. Cardiovasc Res. 2003 Feb;57(2):434-42. doi: 10.1016/s0008-6363(02)00704-6. Cardiovasc Res. 2003. PMID: 12566116

5

The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities.

De Boer RA, Pinto YM, Van Veldhuisen DJ. De Boer RA, et al. Microcirculation. 2003 Apr;10(2):113-26. doi: 10.1038/sj.mn.7800188. Microcirculation. 2003. PMID: 12700580 Review.

6

Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats.

de Borst MH, Navis G, de Boer RA, Huitema S, Vis LM, van Gilst WH, van Goor H. de Borst MH, et al. Among authors: de boer ra. Lab Invest. 2003 Dec;83(12):1761-70. doi: 10.1097/01.lab.0000101731.11015.f6. Lab Invest. 2003. PMID: 14691294 Free article.

7

Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.

de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F, van Gilst WH, van Veldhuisen DJ, Pinto YM. de Boer RA, et al. J Mol Med (Berl). 2004 Oct;82(10):678-87. doi: 10.1007/s00109-004-0579-3. Epub 2004 Aug 20. J Mol Med (Berl). 2004. PMID: 15322702

8

Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury.

van der Meer P, Lipsic E, Henning RH, de Boer RA, Suurmeijer AJ, van Veldhuisen DJ, van Gilst WH. van der Meer P, et al. Among authors: de boer ra. Eur J Heart Fail. 2004 Dec;6(7):853-9. doi: 10.1016/j.ejheart.2004.03.012. Eur J Heart Fail. 2004. PMID: 15556046 Free article.

9

The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy.

van der Meer P, De Boer RA, White HL, van der Steege G, Hall AS, Voors AA, van Veldhuisen DJ. van der Meer P, et al. Among authors: de boer ra. J Card Fail. 2005 May;11(4):279-84. doi: 10.1016/j.cardfail.2004.11.006. J Card Fail. 2005. PMID: 15880336 Clinical Trial.

10

Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial.

de Boer RA, Hillege HL, Tjeerdsma G, Verheugt FW, van Veldhuisen DJ. de Boer RA, et al. Thromb Res. 2005;116(4):279-85. doi: 10.1016/j.thromres.2004.12.008. Epub 2005 Jan 18. Thromb Res. 2005. PMID: 16038711 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

702 results

Search Page

Filters